Patents by Inventor Mark Hsieh

Mark Hsieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10625000
    Abstract: The invention relates to a method for estimating a negative pressure at a wound site during a negative pressure wound therapy. The method comprises the steps of determining a negative pressure value by means of a pressure sensor, determining a pump speed associated with the electrical pump, multiplying the pump speed by a constant to obtain a modification value, and combining said modification value with the negative pressure value determined by means of the pressure sensor to obtain a modified negative pressure value. Said modified negative pressure value corresponds to the estimated negative pressure present at the wound site. The invention further relates to a negative pressure wound therapy system adapted to execute said method of estimating a negative pressure at a wound site.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: April 21, 2020
    Assignee: Paul Hartmann AG
    Inventors: Pierre Croizat, Jürgen Hofstetter, James Stein, Chris Dawber, Mark Hsieh
  • Publication number: 20190298931
    Abstract: Disclosed are systems and methods of detecting an impulse of energy given off by an injection device and determining a dosage of medicine based on the impulse. In one example, a module detects the vibrations given off by dialing a click-wheel on an autoinjector and determining the selected dosage of medicine based on the dialed dosage.
    Type: Application
    Filed: April 15, 2019
    Publication date: October 3, 2019
    Inventors: Mircea Stefan Despa, Harry Bullivant, Andrew Richards, Michael Allan, Mark Hsieh, Sundeep Kankanala, Dylan Wilson
  • Patent number: 10258745
    Abstract: Disclosed are systems and methods of detecting an impulse of energy given off by an injection device and determining a dosage of medicine based on the impulse. In one example, a module detects the vibrations given off by dialing a click-wheel on an autoinjector and determining the selected dosage of medicine based on the dialed dosage.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: April 16, 2019
    Assignee: Becton, Dickinson and Company
    Inventors: Mircea Stefan Despa, Harry Bullivant, Andrew Richards, Michael Allan, Mark Hsieh, Sundeep Kankanala, Dylan Wilson
  • Publication number: 20170209630
    Abstract: A portable negative pressure wound therapy device adapted to be carried by a user, comprising an electrically actuated suction pump for draining wound fluids from a patient, at least one microelectronic controller, at least one electronic memory and a housing for containing the electrical and/or electronic components. The device further comprises at least one microelectronic impact sensor, wherein the impact sensor is adapted to detect an impact acting on the device.
    Type: Application
    Filed: December 23, 2016
    Publication date: July 27, 2017
    Inventors: Johanna Klusmann, Karina Beyrle, Axel Eckstein, Jürgen Hofstetter, Pierre Croizat, Mark Hsieh, James Stein, Chris Dawber
  • Publication number: 20170189588
    Abstract: The invention relates to a method for estimating a negative pressure at a wound site during a negative pressure wound therapy. The method comprises the steps of determining a negative pressure value by means of a pressure sensor, determining a pump speed associated with the electrical pump, multiplying the pump speed by a constant to obtain a modification value, and combining said modification value with the negative pressure value determined by means of the pressure sensor to obtain a modified negative pressure value. Said modified negative pressure value corresponds to the estimated negative pressure present at the wound site. The invention further relates to a negative pressure wound therapy system adapted to execute said method of estimating a negative pressure at a wound site.
    Type: Application
    Filed: December 23, 2016
    Publication date: July 6, 2017
    Inventors: Pierre Croizat, Jürgen Hofstetter, James Stein, Chris Dawber, Mark Hsieh
  • Publication number: 20160213853
    Abstract: Disclosed are systems and methods of detecting an impulse of energy given off by an injection device and determining a dosage of medicine based on the impulse. In one example, a module detects the vibrations given off by dialing a click-wheel on an autoinjector and determining the selected dosage of medicine based on the dialed dosage.
    Type: Application
    Filed: January 21, 2016
    Publication date: July 28, 2016
    Inventors: Mircea Despa, Harry Bullivant, Andrew Richards, Michael Allan, Mark Hsieh, Sundeep Kankanala, Dylan Wilson
  • Publication number: 20150368344
    Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.
    Type: Application
    Filed: June 19, 2015
    Publication date: December 24, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Barbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Maribel Beaumont, Holly Cherwinski, Mark Hsieh, Sabrina Benchaar, Joseph H. Phillips
  • Patent number: 8877900
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: November 4, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter Peizhi Luo, Kevin Caili Wangr, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon, Sujata Sharma, Jon Condra, Jun Lu, Gopalakrishnan Parthasarathy, Stephen Soisson, Noel Byrne
  • Publication number: 20140227719
    Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.
    Type: Application
    Filed: September 17, 2012
    Publication date: August 14, 2014
    Inventors: Barbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Marbel Beaumont, Holly Cherwinski, Mark Hsieh, Sabrina Benchaar, Joseph H. Philips
  • Patent number: 8802827
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 12, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter Peizhi Luo, Kevin Caili Wang, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon
  • Publication number: 20140121123
    Abstract: The invention provides methods of introducing diversity into antibody molecules comprising introducing or substituting at least one amino acid sequence in the CDR of the target antibody together with at least one amino acid in the FW region spanning the 3 amino acid adjoining the CRD on each side. The resulting diverse antibodies with variant CDRs and FW region sequences comprising diverse amino acid sequences are also described. These polypeptides regions, herein referred to as 3+CDR3+, that form the gist of the invention contribution described herein provide a flexible and simple source of sequence diversity that can be used as a source for expressing and identifying diverse antibodies or antigen binding polypeptides. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.
    Type: Application
    Filed: October 24, 2011
    Publication date: May 1, 2014
    Inventors: Kevin Caili Wang, Yan Li, Mark Hsieh, Xinwei Wang, Xinwei Wang, Feng Dong, Peizhi (Peter) Luo, Pingyu Zhong
  • Publication number: 20120231005
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Application
    Filed: October 29, 2010
    Publication date: September 13, 2012
    Inventors: Peter Peizhi Luo, Kevin Caili Wang, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon
  • Publication number: 20120213794
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Application
    Filed: October 29, 2010
    Publication date: August 23, 2012
    Inventors: Peter Peizhi Luo, Kevin Caili Wangr, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon, Sujata Sharma, Jon Condra, Jun Lu, Gopalakrishnan Parthasarathy, Stephen Soisson, Noel Byrne
  • Publication number: 20120129702
    Abstract: The present invention provides a structure-based methodology for efficiently generating and screening a library of recombinant antibodies for optimized antibodies with desirable functions, such as higher binding affinity or low immunogenicity. In one embodiment, a method is provided for constructing a library of antibody sequences based on a three dimensional structure of a lead antibody. The method comprises: providing a lead structural template comprising the amino acid sequence of the variable region of the heavy chain (VH) or light chain (VL) of a lead antibody, comparing the lead template sequence with a plurality of tester protein sequences; selecting a hit library from the tester protein sequences; determining if a member of the hit library is structurally compatible with the lead structural template using a scoring function; selecting members for the hit library that score equal to or better than the lead sequence and screening members for improved function(s).
    Type: Application
    Filed: October 28, 2010
    Publication date: May 24, 2012
    Inventors: Peizhi Luo, Mark Hsieh, Pingyu Zhong, Caili Wang
  • Publication number: 20110257044
    Abstract: Methods and systems are provided for constructing recombinant antibody libraries based on three-dimensional structures of antibodies from various species including human. In one aspect, a library of antibodies with diverse sequences is efficiently constructed in silico to represent the structural repertoire of the vertebrate antibodies. Such a functionally representative library provides a structurally diverse and yet functionally more relevant source of antibody candidates which can then be screened for high affinity binding to a wide variety of target molecules, including but not limited to biomacromolecules such as protein, peptide, and nucleic acids, and small molecules.
    Type: Application
    Filed: December 16, 2008
    Publication date: October 20, 2011
    Inventors: Peizhi Luo, Mark Hsieh
  • Patent number: 8030469
    Abstract: The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: October 4, 2011
    Assignee: SBI Incubation Co., Ltd.
    Inventors: Teikichi Aoyagi, Peter Peizhi Luo, Pingyu Zhong, Mark Hsieh, Yan Li, Kevin Caili Wang, Chikao Morimoto
  • Publication number: 20110124528
    Abstract: The present invention provides a methodology for efficiently generating and screening protein libraries for optimized proteins with desirable biological functions, such as improved binding affinity towards biologically and/or therapeutically important target molecules. The process is carried out computationally in a high throughput manner by mining the ever-expanding databases of protein sequences of all organisms, especially human.
    Type: Application
    Filed: October 29, 2010
    Publication date: May 26, 2011
    Inventors: Peizhi Luo, Mark Hsieh, Pingyu Zhong, Caili Wang, Yicheng Cao, Shengjiang Liu
  • Patent number: 7667004
    Abstract: Methods are provided for designing and selecting antibodies against human antigens with high affinity and specificity in silico and in vitro. In some particular embodiments, methods are provided for designing and selecting humanized or fully human antibodies against vascular endothelial growth factor (VEGF) with high affinity and specificity. In another aspect of the invention, monoclonal antibodies against VEGF are provided. In particular, humanized or human anti-VEGF monoclonal antibodies are provided with ability to bind to human VEGF with high affinity, inhibit VEGF-induced proliferation of endothelial cells in vitro and inhibit VEGF-induced angiogenesis in vivo. These antibodies and their derivative can be used in a wide variety of applications such as diagnosis, prevention, and treatment of diseases such as cancer, AMD, diabetic retinopathy, and other diseases derived from pathological angiogenesis.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: February 23, 2010
    Assignee: Abmaxis, Inc.
    Inventors: Pingyu Zhong, Peizhi Luo, Kevin C. Wang, Mark Hsieh, Yan Li
  • Patent number: 7545662
    Abstract: A circuit with an inter-module radiation interference shielding mechanism is disclosed. The circuit includes a circuit module producing a radiation field. At least one radiation shielding module is situated between the circuit module and another module that is vulnerable to the interference of the radiation field. The shielding module is substantially tangential to the radiation field.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: June 9, 2009
    Assignee: Taiwan Semiconductor Manufacturing Co., Ltd.
    Inventors: Chao-Hsiung Wang, Horng-Huei Tseng, Denny Tang, Wen-Chin Lin, Mark Hsieh
  • Publication number: 20090136523
    Abstract: The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.
    Type: Application
    Filed: November 3, 2008
    Publication date: May 28, 2009
    Applicant: Y's Therapeutics Co, Ltd.
    Inventors: Teikichi Aoyagi, Peter Peizhi Luo, Pingyu Zhong, Mark Hsieh, Yan Li, Kevin Caili Wang, Chikao Morimoto